Video

Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

Author(s):

Joyce O’Shaughnessy, MDVirginia Borges, MD

The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.

Related Videos
Alastair Thompson, BSc, MBChB, MD, FRCS
Adam M. Brufsky, MD, PhD, FACP
Sara M. Tolaney, MD, MPH
Chirag Shah, MD
Jason A. Mouabbi, MD
5 KOLs are featured in this program
5 KOLs are featured in this program
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
2 KOLs are featured in this program.
Related Content
Paolo Tarantino, MD, of Dana-Farber Cancer Institute
July 24th 2024

Pending Dato-DXd Approval Solidifies Importance of Sequencing in HR+ Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Lisa Conte
July 23rd 2024

Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Sonya Reid, MD, MPH
July 22nd 2024

Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer

Pedram Razavi, MD, PhD
July 22nd 2024

Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management